Skip to main content
 

Cipherome

Cipherome

Cipherome was founded on the belief that everyone deserves the best medicine: serious adverse drug reactions (ADRs) occur in certain individuals, but not in others due, in part, to clinical factors in the presence of inherited genomic variants. Cipherome’s proprietary clinical genomics platform leverages explainable AI and ML to reduce ADRs and improve outcomes by personalizing drug treatment. Our platform is in clinical development to improve outcomes for patients with heart disease (stable ischemic heart disease, atrial fibrillation or venous thromboembolism), gastrointestinal disease (IBD, Crohn’s), cancer (pediatric acute lymphoblastic leukemia).

More News

Sign up for our mailing list